Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-32.43% Downside)
Action:ReiteratedDate:01/22/26
The score is held down primarily by weak financial performance (persistent losses, worsening cash burn, and a more pressured balance sheet) and bearish technical signals (price below key moving averages with negative MACD). Offsetting factors include strong recent revenue growth and a strategic pivot highlighted on the earnings call, but ongoing cost escalation and the need for bridge/equity financing keep risk elevated, while valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Revenue Momentum
Sustained revenue acceleration from the acquisition-led strategy demonstrates real demand traction and a scalable growth vector. The 76% Q3 jump reflects expanding service and treatment volumes that can compound over quarters as the company integrates centers and leverages referrals, improving fixed-cost absorption and long-term revenue base.
Negative Factors
Persistent Cash Burn
Chronic negative operating and free cash flow near -$14.4M TTM creates an ongoing funding requirement and heightens dilution and refinancing risk. Without a clear path to sustained positive cash generation, the company must rely on external capital to support operations and acquisitions, limiting strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Sustained revenue acceleration from the acquisition-led strategy demonstrates real demand traction and a scalable growth vector. The 76% Q3 jump reflects expanding service and treatment volumes that can compound over quarters as the company integrates centers and leverages referrals, improving fixed-cost absorption and long-term revenue base.
Read all positive factors
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.93M
Dividend YieldN/A
Average Volume (3M)421.86K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth18.76%
EPS Growth60.09%
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,467,788
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.71
Price to Sales (P/S)1.43
P/FCF Ratio-1.62
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$2.50Price Target Upside12.61% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.28
Revenue Forecast (FY)$29.01M
Vivos Therapeutics Business Overview & Revenue Model
Company Description
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasiv...
How the Company Makes Money
Vivos Therapeutics generates revenue primarily through the sale of its patented medical devices and treatment systems for sleep apnea. The company operates a direct-to-consumer model as well as a business-to-business model, partnering with dental ...
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:Nov 19, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The earnings call displayed strong revenue growth and strategic steps towards expanding market presence through the acquisition and alliance models. However, increased operational costs and net loss pose challenges. Despite these hurdles, the company is optimistic about its new business model and future revenue potential.Positive Updates
Significant Revenue Growth
For the third quarter of 2025, revenue increased 76% to $6.8 million compared to $3.9 million in Q3 2024 and 78% sequentially versus second quarter of 2025.
Negative Updates
Increased Costs and Net Loss
General and administrative expenses increased by approximately $5.7 million or 42% to $19.2 million. Net loss increased to $5.4 million in Q3 and $14.3 million for the full 3 quarters of 2025.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant Revenue Growth
For the third quarter of 2025, revenue increased 76% to $6.8 million compared to $3.9 million in Q3 2024 and 78% sequentially versus second quarter of 2025.
Read all positive updates
Company Guidance
During the Vivos Third Quarter 2025 Conference Call, the company announced a notable 76% increase in revenue, reaching $6.8 million compared to $3.9 million in Q3 2024, driven by the acquisition of the Sleep Center of Nevada and strategic alliances. This revenue surge was primarily attributed to a $2.7 million increase in service revenue and a $200,000 rise in product revenue, with significant contributions from OSA sleep testing services and new treatment centers. Despite a $5.4 million net loss in Q3, reflecting increased operational costs and strategic investments, Vivos expressed confidence in the growth trajectory and potential profitability of their new business model, which focuses on medical sleep practice acquisitions and affiliations. The company highlighted a significant shift from their legacy business model, with decreased reliance on VIP enrollment revenue, and projected further growth as they expand their market presence and optimize operational efficiencies.Vivos Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.32M | 15.03M | 13.80M | 16.02M | 16.89M | 13.07M |
| Gross Profit | 9.65M | 9.02M | 8.27M | 10.02M | 12.60M | 10.41M |
| EBITDA | -15.97M | -10.55M | -16.68M | -24.36M | -19.54M | -11.24M |
| Net Income | -17.10M | -11.14M | -13.58M | -23.84M | -20.29M | -12.06M |
Balance Sheet | ||||||
| Total Assets | 25.64M | 15.28M | 10.73M | 13.72M | 33.69M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 3.09M | 6.26M | 1.64M | 3.52M | 24.03M | 18.21M |
| Total Debt | 12.50M | 1.51M | 2.00M | 2.41M | 1.63M | 1.29M |
| Total Liabilities | 23.11M | 7.33M | 10.32M | 8.92M | 8.15M | 8.41M |
| Stockholders Equity | 2.53M | 7.95M | 411.00K | 4.80M | 25.54M | 16.92M |
Cash Flow | ||||||
| Free Cash Flow | -14.43M | -13.26M | -12.75M | -20.51M | -18.13M | -5.80M |
| Operating Cash Flow | -14.39M | -12.69M | -11.95M | -19.59M | -15.73M | -5.68M |
| Investing Cash Flow | -6.11M | -568.00K | -853.00K | -924.00K | -2.61M | -120.25K |
| Financing Cash Flow | 17.28M | 17.88M | 10.92M | 0.00 | 24.17M | 23.54M |
Vivos Therapeutics Technical Analysis
Negative
2.22
Price Trends
1.54
Negative
1.89
Negative
2.90
Negative
Market Momentum
-0.11
Positive
28.42
Positive
7.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.22 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.54, and below the 200-day MA of 2.90, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 28.42 is Positive, neither overbought nor oversold. The STOCH value of 7.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $52.60M | -0.49 | 129.49% | ― | -25.18% | -9.71% | |
46 Neutral | $22.78M | -3.11 | -148.64% | ― | 4.58% | 55.26% | |
44 Neutral | $4.13M | -0.55 | -70.27% | ― | -87.84% | 29.16% | |
43 Neutral | $11.93M | -1.57 | -335.47% | ― | 18.76% | 60.09% | |
43 Neutral | $26.05M | -0.74 | -210.36% | ― | -70.54% | 70.03% |
* Healthcare Sector Average
VVOS
Vivos Therapeutics
1.14
-2.05
-64.26%
IRIX
Iridex
1.33
0.44
50.57%
CODX
Co-Diagnostics
1.97
-9.77
-83.23%
ADGM
Adagio Medical Holdings
1.23
0.28
29.47%
COCH
Envoy Medical
0.68
-0.70
-50.61%
NXL
Nexalin Technology, Inc.
0.40
-1.66
-80.78%
Vivos Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Vivos Therapeutics Completes Warrant Inducement Financing Transaction
Neutral
Jan 20, 2026
On January 15, 2026, Vivos Therapeutics entered into a warrant inducement agreement with an institutional holder under which the investor agreed to exercise in full previously issued warrants from January 2023, November 2023 and February 2024 at a...
Private Placements and Financing
Vivos Therapeutics Secures Convertible Bridge Financing Facility
Positive
Jan 16, 2026
On January 15, 2026, Vivos Therapeutics, Inc. entered into an unsecured, non‑interest‑bearing (absent default) convertible promissory note of up to $5.5 million in maximum principal with V-Co Investors 3 LLC, an affiliate of existing p...
Private Placements and Financing
Vivos Therapeutics Secures $2M Note with Avondale
Neutral
Dec 5, 2025
On December 5, 2025, Vivos Therapeutics, Inc. entered into a Note Purchase Agreement with Avondale Capital, LLC, resulting in a $2,093,340 promissory note. The company received approximately $1,500,000 in net proceeds, which it intends to use for ...
Business Operations and StrategyShareholder Meetings
Vivos Therapeutics Holds Annual Stockholders Meeting
Neutral
Nov 4, 2025
On November 4, 2025, Vivos Therapeutics, Inc. held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and strategic direction. The stockholders elected six directors to the board for a one-ye...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.